Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22538981 | 0.81 | HTR1A (0.36) | NPC1RAB9AHTR1AHCRTR2HCRTR1 | |
| SCHEMBL19793343 | 0.76 | HCRTR2 (0.36) | HCRTR2HCRTR1 | |
| SCHEMBL17525630 | 0.76 | MEN1 (0.36) | NPC1RAB9AHTR1ADPP4DPP8 | |
| SCHEMBL22538918 | 0.74 | FDPS (0.35) | HCRTR2HCRTR1 | |
| SCHEMBL19793300 | 0.74 | KDM4E (0.34) | HCRTR2HCRTR1 | |
| SCHEMBL25615350 | 0.73 | — | — | |
| SCHEMBL19590974 | 0.73 | HCRTR1 (0.35) | HCRTR2HCRTR1 | |
| SCHEMBL20880132 | 0.71 | TERT (0.39) | — | |
| SCHEMBL22538976 | 0.69 | EPHX1 (0.40) | HCRTR2HCRTR1 | |
| SCHEMBL20880100 | 0.67 | HCRTR1 (0.53) | NPC1RAB9AHTR1AHCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016256-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016256-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, GOT2, GLS | NPC1 1704/4885RAB9A 2778/4885HTR1A 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.